RAS mutation analysis in a large cohort of Chinese patients with acute myeloid leukemia

Yang, Xiaofei; Qian, Jun; Sun, Aining; Jiang, Lin; Xiao, Gao-Fei; Yin, Jia; Chen, Suning; Wu, Depei

doi:10.1016/j.clinbiochem.2012.12.022

Cited by 55 publications

(40 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, the frequencies of NPM1 and FLT3 -ITD mutations were 15.1 and 14.5%, which were obviously lower than those reported in Germany (27.5 and 21.0%) [11] and Japan (24.9 and 22.6%) [16], but approximated to those reported in large cohorts of Chinese AML patients (16.4 and 13.5%) [17,18]. Mutations in the c-kit gene occur in about 6% of all patients and 30% of patients with t(8;21)(q22;q22) or inv(16)(p13q22) [13], which could also be observed in this study (7.9 and 24.0%, respectively).…”

Section: Discussioncontrasting

confidence: 47%

The Surface Molecular Signature of Leukemic Cells Is Associated with NPM1 Mutations and FLT3-ITD in Patients with de novo Acute Myeloid Leukemia

Gao²,

Li³

et al. 2013

Acta Haematol

View full text Add to dashboard Cite

Certain molecular mutations are associated with signs of cell morphology and differentiation in acute myeloid leukemia (AML). However, only limited data are available for the detailed analysis of such correlations. In this study, AML patients were classified into 4 subsets according to CD34, HLA-DR and CD11c expression levels. Significantly low CD34 antigen expression was observed in nucleophosmin (NPM1)-mutated patients and in those with FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD). No correlations were observed among NPM1 mutations, FLT3-ITD and monocytic morphology in patients without CD34 expression. Both NPM1 mutations and FLT3-ITD were absent in cluster IIb patients (CD34⁺CD11c^-). The associations among NPM1 mutations, FLT3-ITD and the surface molecular signature of leukemic cells may offer beneficial information about the pathogenesis of AML.

show abstract

Section: Discussioncontrasting

confidence: 47%

The Surface Molecular Signature of Leukemic Cells Is Associated with NPM1 Mutations and FLT3-ITD in Patients with de novo Acute Myeloid Leukemia

Gao²,

Li³

et al. 2013

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…[21][22][23][24] All positive samples were confirmed by direct DNA sequencing. FLT3-ITD and CEBPA mutations were detected by direct DNA sequencing (BGI Tech Solutions Co., Shanghai, China).…”

Section: Rna Isolation Reverse Transcription and Realtime Quantitatmentioning

confidence: 92%

LowNKD1expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia

et al. 2017

Self Cite

View full text Add to dashboard Cite

Dysregulation of NKD1 has been identified in several solid tumors. However, the status of NKD1 expression and its clinical implication in acute myeloid leukemia remain largely elusive. NKD1 transcript level in bone marrow mononuclear cells was detected by real-time quantitative polymerase chain reaction in 126 de novo acute myeloid leukemia patients and 30 controls. Clinical significance of NKD1 expression was obtained by the comparison between the patients with low and high NKD1 expression. NKD1 messenger RNA level was significantly decreased in acute myeloid leukemia patients compared with controls (p = 0.019). There were no significant differences between patients with low and high NKD1 expression in sex, age, peripheral blood cells, bone marrow blasts, French-American-British/World Health Organization subtypes, and karyotypes/karyotypic classifications (p > 0.05). Although no significant difference was observed in complete remission rate between NKD1 low and NKD1 high patients (p > 0.05), Kaplan-Meier analysis revealed that NKD1 low patients showed shorter overall survival time than NKD1 high patients in whole-cohort acute myeloid leukemia, non-M3 acute myeloid leukemia, and cytogenetically normal acute myeloid leukemia (p = 0.014, 0.063, and 0.020). Multivariate analyses disclosed the low NKD1 expression was an independent risk factor in cytogenetically normal acute myeloid leukemia patients (hazard ratio = 0.397, p = 0.017). Moreover, the prognostic value of NKD1 expression was confirmed by gene expression profile data in cytogenetically normal acute myeloid leukemia patients (p = 0.028 and 0.011). NKD1 showed significantly increased level after induction chemotherapy achieved complete remission in follow-up paired acute myeloid leukemia patients (p < 0.001). These findings indicated that reduced NKD1 expression is associated with unfavorable clinical outcome in cytogenetically normal acute myeloid leukemia.

show abstract

“…The frequencies of mutations of N-Ras and K-Ras are 9.7% and 2.9% in Chinese patients with acute myeloid leukemia (AML) [13]. H-Ras is localized predominantly in disordered plasma membrane and cholesterol-rich lipid rafts [14].…”

Section: Introductionmentioning

confidence: 99%

Differentiation and apoptosis induction by lovastatin and γ-tocotrienol in HL-60 cells via Ras/ERK/NF-κB and Ras/Akt/NF-κB signaling dependent down-regulation of glyoxalase 1 and HMG-CoA reductase

Chen

Liu

Huang

et al. 2015

Cellular Signalling

View full text Add to dashboard Cite

RAS mutation analysis in a large cohort of Chinese patients with acute myeloid leukemia

Cited by 55 publications

References 27 publications

The Surface Molecular Signature of Leukemic Cells Is Associated with <b><i>NPM1</i></b> Mutations and <b><i>FLT3</i></b>-ITD in Patients with de novo Acute Myeloid Leukemia

The Surface Molecular Signature of Leukemic Cells Is Associated with <b><i>NPM1</i></b> Mutations and <b><i>FLT3</i></b>-ITD in Patients with de novo Acute Myeloid Leukemia

LowNKD1expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia

Differentiation and apoptosis induction by lovastatin and γ-tocotrienol in HL-60 cells via Ras/ERK/NF-κB and Ras/Akt/NF-κB signaling dependent down-regulation of glyoxalase 1 and HMG-CoA reductase

Contact Info

Product

Resources

About